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In response to requests for the funding of 
new drugs, reimbursement agencies are 
re-evaluating some of the methods used in 
assessing these products. Many trials submit-
ted for the regulatory review of new drugs do 
not provide adequate data for subsidy deci-
sions. We argue that all involved in bringing 
medicines to market need to be explicit 
about the additional information required, 
decide how these data should be collected 
and assessed and the methods that should 
be used to set a fair price for a new drug.
In Australia, a formal appraisal of the 
cost–effectiveness and budget impact of a 
new medicine precedes any subsidy deci-
sion at national level.1 If a new product is 
subsidized, the government pays an agreed 
price to the manufacturer, sometimes with 
requirements for financial contracts to 
manage expenditure.2
Increasingly, patients are asking for 
early access to new drugs, particularly for 
treating cancer. In consequence, strategies 
to subsidize drugs for use under conditions 
of coverage with evidence development or 
managed entry are being proposed. A new 
drug might be approved even if there is no 
evidence to show that it satisfies the stan-
dards typically applied in health technology 
assessments. However, this approval is often 
contingent upon additional requirements 
for subsequent randomized trials or the 
collection of data on the drug’s effectiveness 
and safety in practice. There is no consensus 
on the best methods for identifying drugs 
appropriate for managed entry schemes, for 
collecting post-approval data or for the use of 
such data to modify decisions about coverage. 
In Australia, as in many other countries, 
several questions need to be answered. Can 
stakeholders produce a workable framework 
for managed entry schemes? What can be 
done to reduce variation in the inputs used 
for cost–effectiveness models? How can 
drug or disease registries contribute useful 
information to inform reimbursement deci-
sions? How should registry data be evalu-
ated? What can be done to make registry 
data more representative of the population 
and what types of post-progression data 
should be included in trials of targeted 
cancer therapies?
Regulatory agencies, insurers and 
clinicians also need to be able to deter-
mine if a new drug represents good value 
for money and what to do if an effective 
drug appears too highly priced for the 
benefit that it offers. The prices of several 
recently-introduced drugs – for example 
aflibercept, ivacaftor and sofosbuvir – have 
been questioned.3-5
The way in which drug prices change 
over time has generally been a function 
of the market. Typically, a new drug is 
launched under patent and can command 
a good price until the patent expires and 
competition and/or generic products 
emerge. Exceptionally, public pressure 
and legal challenges decreased the price 
of several antiretroviral drugs in countries 
with high burdens of human immunode-
ficiency virus before patent expiry.6 Other 
strategies, such as compulsory licensing, 
have had limited success.7 Tiered pricing 
has also been proposed but defining each 
tier and an appropriate price for each has 
proved challenging.8 The recent approval of 
high-priced medicines for many conditions 
has prompted a new round of discussions9 
and calls for radical changes to the current 
commercial model for drug development.10
We consider that it is time for a global 
forum to discuss objectivity and equity in 
access to high-priced drugs. Such a forum 
should extend beyond the usual networks 
of payers and authorities on health tech-
nology assessment. It needs to define the 
methods needed to manage the early entry 
of promising products – i.e. how to evaluate 
the data that are available for early market 
entry, determine an appropriate initial 
price, optimize the collection of data from 
clinical practice, enable independent tri-
als and manage the exit of products that, 
in practice, are found to be insufficiently 
effective. The forum should promote the 
development of a method for pricing new 
drugs. Such a method needs to reconcile the 
need for fair pricing, with the difficulties of 
obtaining accurate information on research, 
development and manufacturing costs. 
The forum should include representatives 
of patient and consumer groups, so that 
the right questions are asked, appropriate 
research priorities are set and outcomes are 
communicated. 
In managing access to new drugs, 
simply continuing to react country-by-
country and disease-by-disease is not 
sustainable. We need to be more forward-
thinking and take some of the pressure 
off small purchasers and countries that 
are currently trying to make equitable 
decisions in isolation. We need to solve 
the fundamental problem of how to bal-
ance objectivity of appraisal and equity 
in access to new products; ensuring that 
medical advances are affordable, working 
with a viable pharmaceutical industry that 
responds to public health needs. ■
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